3',4'-dimethoxyl-4-nitrostilbene | 110997-71-2

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 英文名称: 3',4'-dimethoxyl-4-nitrostilbene
• 英文别名: 3,4-dimethoxyl-4'-nitrodiphenylethylene；1,2-dimethoxy-4-[2-(4-nitrophenyl)ethenyl]benzene
• CAS: 110997-71-2
• 化学式: C₁₆H₁₅NO₄
• 分子量: 285.299
• InChiKey: GEEZQNAIPKZMRR-UHFFFAOYSA-N

物化性质

• 沸点：
  417.7±35.0 °C(Predicted)
• 密度：
  1.227±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  64.3
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3',4'-dimethoxyl-4-nitrostilbene 在 tin(II) chloride dihdyrate 作用下， 以 乙醇 为溶剂， 反应 24.0h， 以46%的产率得到3,4-dimethoxyl-4'-aminediphenylethylene
  参考文献：
  名称：

  含有亚氨基和羟基的新型双光子吸收有机发色团：合成，ESIPT和化学传感器

  摘要：

  在这项工作中，提出了多种含有亚氨基和羟基的新型共轭生色团。调查了这些生色团在单光子和双光子照射下的激发态分子内质子转移（ESIPT）。单光子吸收光谱表明，在含有邻羟基的有机染料中存在内部氢键，而带有对羟基的相应染料则没有分子内的氢键作用。相反，在大多数非质子和质子溶剂中，带有邻羟基的扩展发色 团显示出良好分离的双发射带，斯托克斯位移大（约160 nm），而含有对羟基苯甲酸的分子-羟基基团仅显示具有正常Stokes位移（约50 nm）的单个谱带。还可以通过近红外（近红外）飞秒激光对带有邻羟基的分子观察到双光子吸收（TPA）引起的竞争性ESIPT发射。实验表明，带有邻羟基的分子在单光子和双光子激发下能够进行ESIPT，而含有对羟基的分子则没有这种特性。2-（（（3'，4'-二甲氧基-苯基亚乙基-苯基-4-ylimino）甲基）苯酚（C1）和2-（（3'，4'，5'-三甲氧基-苯基亚乙基-苯基-

  DOI：

  10.1016/j.tet.2013.04.121
• 作为产物：
  描述：

  3,4-二甲氧基苄氯 在 sodium hydride 作用下， 以 四氢呋喃 、 甲苯 为溶剂， 反应 6.0h， 生成 3',4'-dimethoxyl-4-nitrostilbene
  参考文献：
  名称：

  Design, synthesis and antitumour and anti-angiogenesis evaluation of 22 moscatilin derivatives

  摘要：

  Two series of moscatilin derivatives were designed, synthesized and evaluated as anti-tumor and anti-angiogenesis agents. Most of these compounds showed moderate-to-obvious cytotoxicity against five cancer cell lines (A549, HepG2, MDA-MB-231, MKN-45, HCT116). Among these cell lines, compounds had obvious effects on HCT116. Especially for 8Ae, the IC50 was low to 0.25 mu M. 8Ae can inhibit the viability and induce the apoptosis of HCT116 cells but exhibit no cytotoxic activity in noncancerous NCM460 colon cells. 8Ae can also arrest the G2/M cell cycle in HCT116 cells by inhibiting the alpha-tubulin expression. Zebrafish bioassay-guided screen showed the 22 moscatilin derivatives had potent anti-angiogenic activities and compound 8Ae had better activities than positive compound. Molecular docking indicated 8Ae interacted with tubulin at the affinity of -7.2 Kcal/mol. In conclusion, compound 8Ae was a potential antitumor and anti-angiogenesis candidate for further development.

  DOI：

  10.1016/j.bmc.2019.04.027
• 作为试剂：
  描述：

  对硝基苯乙酸 、 3,4-二甲氧基苯甲醛 在 3',4'-dimethoxyl-4-nitrostilbene 作用下， 以 哌啶 为溶剂， 以to yield a yellow solid, 13.4 g (0.047 mol, 34%) of the desired product的产率得到3',4'-dimethoxyl-4-nitrostilbene
  参考文献：
  名称：

  Method of inhibiting amyloid protein aggregation and imaging amyloid deposits

  摘要：

  本发明提供了一种利用I式化合物治疗阿尔茨海默病的方法。同时，本发明还提供了一种利用I式化合物抑制淀粉样蛋白聚集的方法，以及一种成像淀粉样沉积物的方法，以及新的I式化合物。

  公开号：

  US20040220235A1

文献信息

• Anti-influenza activity of phenethylphenylphthalimide analogs derived from thalidomide
  作者：Yuma Iwai、Hitoshi Takahashi、Dai Hatakeyama、Kazunori Motoshima、Minoru Ishikawa、Kazuyuki Sugita、Yuichi Hashimoto、Yuichi Harada、Shigeyuki Itamura、Takato Odagiri、Masato Tashiro、Yoshihisa Sei、Kentaro Yamaguchi、Takashi Kuzuhara

  DOI：10.1016/j.bmc.2010.05.035

  日期：2010.7

  subunits. We identified potential novel anti-influenza agents from a screen of 34 synthesized phenethylphenylphthalimide analogs derived from thalidomide (PPT analogs). For this screen we used a PA endonuclease inhibition assay, a PB2 pathogenicity-determinant domain-binding assay, and an anti-influenza A virus assay. Three PPT analogs, PPT-65, PPT-66, and PPT-67, were found to both inhibit PA endonuclease

  源自猪的甲型流感病毒已在​​全世界引起大流行，甲型流感被认为是严重的全球健康问题。因此，非常需要靶向这些病毒的新型药物。甲型流感病毒表达对其转录和复制必不可少的RNA聚合酶，该酶包含PA，PB1和PB2亚基。我们从34种合成的来自沙利度胺的苯乙基苯基邻苯二甲酰亚胺类似物（PPT类似物）的筛选中鉴定出潜在的新型抗流感药。对于此筛选，我们使用了PA核酸内切酶抑制测定，PB2致病性决定域结合测定和抗A型流感病毒测定。发现三种PPT类似物PPT-65，PPT-66和PPT-67均能抑制PA核酸内切酶活性并延缓甲型流感的生长，表明它们的活性之间存在相关性。还发现PPT-28抑制甲型流感的生长。这四个类似物共有3,4-二羟基苯乙基。我们还讨论了3,4-二羟基苯乙基柔韧性可能在PA核酸内切酶抑制中起重要功能作用的可能性。另一个带有二甲氧基苯乙基的类似物PPT-62具有PB2致病性决定域结合活性，但没有抑
• Al-containing mesoporous carbon as effective catalysts for the chemoselective reduction of carbon–carbon double bonds in nitrostilbene derivatives
  作者：Liuchang Wang、Yanjun Zheng、Xiquan Zhang、Hongmei Gu、Jiang Li、Wei Wang、Baolin Li

  DOI：10.1016/j.apcata.2013.01.040

  日期：2013.4

  reduction of carbon–carbon double bond in 4-nitrostilbene analogs bearing nitro group with hydrazine hydrate. The results indicated that the reduction reaction was able to be achieved successfully between carbon–carbon double bond and nitro group. The efficient method has been developed for the reduction of CC double bonds with diimide, catalytically generated in situ from hydrazine hydrate by the synthesized

  合成了一系列含Al，Mn，Cu和Fe的金属介孔碳催化剂，用于催化水合肼选择性还原带有硝基的4-硝基苯乙烯类似物中的碳-碳双键。结果表明，碳-碳双键与硝基之间能够成功地完成还原反应。已经开发出减少碳含量的有效方法C与二酰亚胺的双键由合成的催化剂由水合肼原位催化生成。0.15Al–MC1作为非均相催化剂在所有合成催化剂中均表现出最高的催化活性和化学选择性。在0.15Al-MC1存在下，在70°C的乙醇中，4-硝基二苯乙烯衍生物中碳-碳双键的还原率高达99％，化学选择性> 99％。另一方面，在惰性气氛下用水合肼，活性炭和FeCl 3 ·6H 2 O也容易实现4-亚硝基苯甲酸酯中硝基的高选择性还原。
• Novel enolamides, process for their manufacture and pharmaceutical compositions thereof with an activity as modulators of the arachidonic acid cascade
  申请人：WARNER-LAMBERT COMPANY

  公开号：EP0221345A1

  公开（公告）日：1987-05-13

  The present invention relates to novel enolamide type compounds, pharmaceutical compositions, and methods of use thereof, useful in the treatment of diseases in which products of lipoxygenase enzyme activity or the action of leukotrienes contribute to the pathological condition.

  本发明涉及新型烯酰胺类化合物、药物组合物及其使用方法，可用于治疗脂氧合酶酶活性产物或白三烯作用导致病理状态的疾病。
• Separation of α-glucosidase-inhibitory and liver X receptor-antagonistic activities of phenethylphenyl phthalimide analogs and generation of LXRα-selective antagonists
  作者：Kazunori Motoshima、Tomomi Noguchi-Yachide、Kazuyuki Sugita、Yuichi Hashimoto、Minoru Ishikawa

  DOI：10.1016/j.bmc.2009.05.066

  日期：2009.7

  Liver X receptor (LXR) alpha/beta dual agonists are candidate medicaments for the treatment of metabolic syndrome, because their biological actions include increasing cholesterol efflux mediated by LXR beta. However, their clinical application is currently limited by their enhancing effect on triglyceride (TG) synthesis mediated by LXR alpha. Combination of an LXR alpha-selective antagonist with an LXR alpha/beta dual agonist may overcome this disadvantage. In the present work, structural development studies of phenethylphenyl phthalimide 9, which possesses LXR alpha/beta dual-antagonistic activity and alpha-glucosidase-inhibitory activity, led to the LXR alpha-selective antagonist 23f. Specific alpha-glucosidase inhibitors were also obtained. (C) 2009 Elsevier Ltd. All rights reserved.
• (N-substituted-2-hydroxy) benzamides and N-substituted-2-hydroxy-alpha-oxo-benzeneacetamides and pharmaceutical compositions thereof having activity as modulators of the arachidonic acid cascade
  申请人：WARNER-LAMBERT COMPANY

  公开号：EP0221346B1

  公开（公告）日：1991-01-30